Bleomycin (sulfate)

CAT: 0804-HY-17565-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-17565-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Bleomycin sulfate is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin sulfate is an antitumor antibiotic[1].
CAS Number
[9041-93-4]
Product Name Alternative
Bleomycin sulfate
UNSPSC
12352211
Hazard Statement
H340, H351, H361
Target
Antibiotic; DNA/RNA Synthesis
Type
Natural Products
Related Pathways
Anti-infection; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Bleomycin-sulfate.html
Purity
99.90
Solubility
DMSO : 41.67 mg/mL (ultrasonic) |H2O : 255 mg/mL (ultrasonic; warming)
Smiles
O=C(C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C)N[C@H](C(N[C@H](C)[C@@H](O)[C@H](C)C(N[C@]([C@H](O)C)([H])C(NCCC2=NC(C3=NC(C(N[R])=O)=CS3)=CS2)=O)=O)=O)[C@H](C4=CN=CN4)O[C@H]5[C@H]([C@H]([C@@H]([C@@H](O5)CO)O)O)O[C@]6([H])[C@H]([C@H]([C@@H]([C@H](O6)CO)O)OC(N)=O)O.NC(NCCCC[R])=N.[R]CCC[S+](C)C.O=S(O)(O)=O.[R=].[BleomycinA2].[R=].[BleomycinB2]
Molecular Weight
1523 (average)
Precautions
H340, H351, H361
References & Citations
[1]Hovhannisyan G, et al. Comparative analysis of individual chromosome involvement in micronuclei induced by bleomycin in human leukocytes. Mol Cytogenet. 2016 Jun 21;9:49.|[2]Jaaskela-Saari HA, et al. Squamous cell cancer cell lines: sensitivity to bleomycin and suitability for animal xenograft studies. Acta Otolaryngol Suppl. 1997;529:241-4.|[3]Corboz MR, et al. Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther. 2018 Apr;49:95-103.|[4]Ling Peng, et al. Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation. Cell Death Dis. 2020 Nov 13;11 (11) :978.|[5]Kang Miao, et al. Scutellarein inhibits BLM-mediated pulmonary fibrosis by affecting fibroblast differentiation, proliferation, and apoptosis. Ther Adv Chronic Dis. 2020 Jul 30;11:2040622320940185.|[6]Brandt JP, et, al. Bleomycin. National Library of Medicine. August 28, 202|[7]Gul A, et, al. Pulmonary fibrosis model of mice induced by different administration methods of bleomycin. BMC Pulm Med. 2023 Mar 21;23 (1) :91.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Natural Products
Clinical Information
Launched
Citation 01
ACS Appl Mater Interfaces. 2019 Jan 16;11 (2) :1942-1950. |Adv Healthc Mater. 2025 Aug 21:e01916.|Am J Physiol Endocrinol Metab. 2024 Oct 1;327 (4) :E552-E562.|Anal Chem. 2025 Jun 3;97 (21) :11073-11081.|Antioxidants (Basel) . 2024 May 29;13 (6) :667.|Biochem Biophys Res Commun. 2020 Jun 30;527 (3) :662-667.|Biochem Cell Biol. 2025 Jan 1:103:1-7.|Biochem Pharmacol. 2020 Apr;174:113846.|Biochem Pharmacol. 2024 Aug 17:116496.|Biochim Biophys Acta Mol Basis Dis. 2025 Mar 12;1871 (5) :167798.|Biochim Biophys Acta Mol Basis Dis. 2026 Feb;1872 (2) :168100.|Biol Proced Online. 2025 Jun 16;27 (1) :21.|Biomed Pharmacother. 2022 Sep:153:113460.|bioRxiv. 2024 July 27.|bioRxiv. 2024 Nov 06.|bioRxiv. 2025 Jul 26.|bioRxiv. 2025 March 11.|bioRxiv. 2025 March 19.|bioRxiv. 2025 May 09.|Cell Calcium. 2025 Oct 22.|Cell Death Dis. 2020 Jun 15;11 (6) :464.|Cell Death Dis. 2020 Nov 12;11 (11) :976.|Cell Death Dis. 2025 Apr 11;16 (1) :278.|Cell Mol Biol Lett. 2024 Aug 30;29 (1) :115.|Cell Mol Life Sci. 2024 Apr 18;81 (1) :187.|Cell Rep. 2024 Sep 28;43 (10) :114794.|Cell Rep. 2025 Mar 12;44 (3) :115399.|Cells. 2021 Jan 20;10 (2) :202.|Cells. 2022 Dec 29;12 (1) :145.|Chinese Journal of Plastic and Reconstructive Surgery. 23 December 2021.|Commun Biol. 2025 Jan 14;8 (1) :51.|Curr Med Sci. 2025 Sep 30.|Cytokine. 2025 Jun 22:193:156978.|Drug Resist Updat. 2026 Jan:84:101319.|Ecotoxicol Environ Saf. 2025 Nov 15:307:119433.|Eur J Med Res. 2025 May 19;30 (1) :394.|Eur J Pharmacol. 2024 Jul 26:176843.|FASEB J. 2025 Oct 15;39 (19) :e71083.|FEBS J. 2024 Nov;291 (21) :4680-4695.|FEMS Yeast Res. 2025 May 22:foaf027.|Front Pharmacol. 2022 May 20;13:911945.|Fundam Res. 2021 Dec 23;2 (1) :37-47.|Gene Rep. 2023 Jul 22, 101823.|Genes Cells. 2025 Jan;30 (1) :e13192.|Heliyon. 2024 Jun 24;10 (13) :e33314.|Int Immunopharmacol. 2023 Mar:116:109723.|Int Immunopharmacol. 2023 Sep 15;124 (Pt A) :110905.|Int Immunopharmacol. 2024 Jul 6:138:112645.|Int Immunopharmacol. 2025 Apr 25:156:114718.|Int Immunopharmacol. 2025 Oct 30:167:115727.|Int Immunopharmacol. 2025 Sep 23:166:115554.|Int J Exp Pathol. 2025 Sep;106 (5) :e70005.|Int J Neurosci. 2025 Aug 7:1-9.|J Adv Res. 2024 Jun 19:S2090-1232 (24) 00254-6.|J Ethnopharmacol. 2024 Apr 25:330:118226.|J Inflamm Res. 2025 Jun 26:18:8447-8475.|J Invest Dermatol. 2023 Jul;143 (7) :1289-1298.e15.|J Med Chem. 2025 Apr 24;68 (8) :8600-8617.|J Vis Exp. 2025 Jun 17: (220) .|J Vis Exp. 2025 Jun 20: (220) .|Mech Ageing Dev. 2024 Apr:218:111902.|Medicina (Kaunas) . 2025 Jun 26;61 (7) :1157.|Mol Med. 2025 Jun 9;31 (1) :222.|Mutat Res Genet Toxicol Environ Mutagen. 2016 Sep 15:808:27-37.|Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397 (11) :8979-8992.|Naunyn Schmiedebergs Arch Pharmacol. 2025 May;398 (5) :5389-5403.|OncoImmunology. 2020 Sep 22;9 (1) :1824631.|Patent. US20190255042A1.|Patent. US20190282565A1.|Pathol Res Pract. 2025 Aug:272:156095.|Phytomedicine. 2023 Apr:112:154707.|Phytomedicine. 2024 Jun 3:131:155797.|Phytomedicine. 2025 Sep 4:147:157227.|Res Sq. 2025 Oct 30.|Research Square Preprint. 2023 Aug 30.|Research Square Preprint. 2023 Nov 23.|Research Square Print. 2025 May 28.|Research Square Print. November 28th, 2022.|Respir Res. 2020 Nov 2;21 (1) :290.|Respir Res. 2020 Feb 19;21 (1) :58. |Sens Actuators B Chem. 2025 Sep 4;446:138682.|STAR Protoc. 2025 Jul 18;6 (3) :103955.|Stem Cell Res Ther. 2025 Aug 5;16 (1) :426.|Stem Cell Res Ther. 2025 Jan 5;16 (1) :2.|Toxicol Appl Pharmacol. 2025 Aug 19:504:117524.|Toxicol Lett. 2022 Jun 15:363:45-54.|Universidad de las Illes Balears. Facultad de Ciencias, 2022 Feb.|ACS Nano. 2025 Apr 15;19 (14) :14028-14043.|Am J Respir Cell Mol Biol. 2021 Aug;65 (2) :189-200.|Am J Respir Cell Mol Biol. 2021 Jul;65 (1) :54-69.|Am J Respir Cell Mol Biol. 2022 Feb;66 (2) :171-182.|Biochem Biophys Res Commun. 2024 Nov 4:739:150951.|Biochem Pharmacol. 2025 Aug 28;242 (Pt 2) :117283.|Biomed Pharmacother. 2021 Jul:139:111500.|Biomed Res Int. 2022 Feb 7;2022:8752325.|Bioorg Med Chem. 2024 Nov 1:113:117924.|Cancer Lett. 2022 Apr 28:532:215588.|Cancers (Basel) . 2024 Aug 21;16 (16) :2902.|Cell Death Dis. 2020 Nov 13;11 (11) :978.|Cell Rep Med. 2025 May 14:102144.|Cell Signal. 2021 Nov:87:110106.|Chin Med. 2023 May 24;18 (1) :60.|Clin Epigenetics. 2023 Nov 11;15 (1) :182.|Exp Mol Med. 2024 Dec;56 (12) :2739-2746.|Heliyon. 2023 Nov 20;9 (12) :e22461.|Heliyon. 2024 Sep 20;10 (19) :e38122.|Immunopharmacol Immunotoxicol. 2020 Oct;42 (5) :436-444.|Int Immunopharmacol. 2025 Apr 16:152:114392.|Int Immunopharmacol. 2026 Jan 1;168 (Pt 1) :115812.|J Adv Res. 2025 Aug 5:S2090-1232 (25) 00587-9.|J Cell Biol. 2021 Feb 1;220 (2) :e201911025.|J Cell Mol Med. 2025 Aug;29 (16) :e70788.|J Control Release. 2023 Aug:360:365-375.|J Inflamm Res. 2024 Jun 19:17:3983-3999.|J Mol Histol. 2025 Nov 24;57 (1) :4.|J Pharmacol Exp Ther. 2025 Jun;392 (6) :103588.|J Transl Med. 2024 Apr 1;22 (1) :323.|J Transl Med. 2024 Nov 21;22 (1) :1051.|J Transl Med. 2025 Jan 2;23 (1) :3.|J Vis Exp. 2025 May 23: (219) .|JACC Basic Transl Sci. 2025 Jul;10 (7) :101255.|Libyan International Journal of Natural Sciences. 2025 May 26.|Life Sci. 2021 Jan 1;264:118664.|MedComm Futur Med. 2024 Jul 19.|Mediators Inflamm. 2022 Mar 3:2022:6755407.|Mol Cell Toxicol. 2025 May 4.|Mol Cell. 2025 Jul 17;85 (14) :2654-2672.e7.|Mol Metab. 2022 Aug:62:101524.|Nat Cell Biol. 2024 Sep;26 (9) :1545-1557.|Nat Commun. 2025 Jul 22;16 (1) :6734.|Nat Metab. 2021 Dec;3 (12) :1706-1726.|Nat Prod Commun. 2024 Mar 29.|Oxid Med Cell Longev. 2021 Jun 29:2021:9926284.|Oxid Med Cell Longev. 2021 Nov 1:2021:6241242.|Pharmaceuticals (Basel) . 2024 Oct 11;17 (10) :1360.|Phytomedicine. 2024 Jul 27:133:155882.|Phytomedicine. 2025 Oct:146:157154.|Phytother Res. 2022 Oct;36 (10) :3911-3923.|Redox Biol. 2021 Oct:46:102082.|Res Sq. 2024 Oct 31.|Res Sq. 2025 May 16.|Research Square Preprint. 2023 Aug 4.|Respir Res. 2024 Oct 19;25 (1) :382.|Respir Res. 2025 Apr 12;26 (1) :136.|Rheumatol Autoimmun. 2024 Jun 28.|Sci China Life Sci. 2023 Nov;66 (11) :2571-2586.|Sci Rep. 2023 Jun 28;13 (1) :10485.|Small. 2021 Nov;17 (47) :e2103919.|SSRN. 2025 Sep 3.|Stem Cells Int. 2025 May 9:2025:1416567.|Ther Adv Chronic Dis. 2020 Jul 30;11:2040622320940185.|Biomed Pharmacother. 2024 Feb:171:116101.|Biomedicines. 2023 Feb 5;11 (2) :463.|BMC Pharmacol Toxicol. 2024 Feb 14;25 (1) :18.|BMC Pulm Med. 2023 Nov 13;23 (1) :440.|Cancer Lett. 2023 Apr 1:558:216092.|Exp Ther Med. 2024 Jan 4;27 (2) :80.|Front Biosci (Landmark Ed) . 2023 Sep 22;28 (9) :209.|Inflammation. 2023 Aug;46 (4) :1531-1542.|Inflammation. 2024 Oct;47 (5) :1744-1761.|Int Immunopharmacol. 2022 Dec;113 (Pt A) :109409.|Int Immunopharmacol. 2023 Jul:120:110369.|Int J Biol Macromol. 2023 Jun 30:241:124476.|J Gene Med. 2022 Sep 30; e3451.|Lab Invest. 2025 Aug 6;105 (11) :104227.|MedComm (2020) . 2023 Jul 12;4 (4) :e319.|Mol Med. 2023 Mar 14;29 (1) :32.|Molecules. 2023 Jan 11;28 (2) :753.|Nat Commun. 2022 Nov 17;13 (1) :7028.|Phytomedicine. 2023 Sep:118:154919.|Research Square Preprint. 2023 Aug 3.|SSRN. 2025 Oct 21.|Transl Res. 2023 Jul:257:54-65.

Related Products

CatalogName
HY-108345Bleomycin
HY-W749297Bleomycin B2
HY-146646Bleomycin A2
HY-N10470-01Bleomycin A5
HY-17565A-01Bleomycin (hydrochloride)
HY-N10469-01Bleomycin B4
HY-125918Bleomycin A5 (hydrochloride)
HY-148649-01Demethyl bleomycin A2
HY-K1053-01Bleomycin D1 Selection Antibiotic, Sterile
HY-P76170-01BLMH/Bleomycin Hydrolase, Mouse (His)

Alternative Products

CatalogName
JH561962Bleomycin sulfate

Popular Products